NCT03009721Unknown不适用
A Non-interventional, Multi-center, Retrospective Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia (ROSE Study)
Daewoong Pharmaceutical Co. LTD.1 个研究点 分布在 1 个国家目标入组 9,707 人开始时间: 2016年8月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 9,707
- 试验地点
- 1
- 主要终点
- Percent change from baseline in blood pressure (SBP/DBP)
研究概览
简要总结
The purpose of this study is to investigate the effectiveness and safety of Olostar Tab in patients with essential hypertension and dyslipidemia
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ≥ 19
- •Patients have record of blood pressure (SBP/DBP) and LDL-C after prescription of Olostar Tab.
排除标准
- •Patients that have participated clinical trials or PMS with Olostar Tab.
结局指标
主要结局
Percent change from baseline in blood pressure (SBP/DBP)
时间窗: At 8 Weeks
Percent change from baseline in LDL-Cholesterol (LDL-C)
时间窗: At 8 Weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar TabHyperlipidemiasHypertensionNCT05411887Daewoong Pharmaceutical Co. LTD.2,845
已完成
2 期
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699Cushing's SyndromeNCT03606408RECORDATI GROUP127
已完成
3 期
Olmesartan Medoxomil Versus Losartan in Patients With HypertensionEssential HypertensionNCT00857285Daiichi Sankyo130
已完成
4 期
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based TherapyRelapsed and/or Refractory Multiple MyelomaNCT03416374Takeda45
已完成
不适用
Investigation of Preservative-Free Ophthalmic Solution in Ocular DrynessDry Eye SyndromesNCT05778942SIFI SpA35